Sensei Biotherapeutics Ownership
| SNSE Stock | USD 0.49 0.03 6.52% |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 25.1 M | Current Value 25.1 M | Avarage Shares Outstanding 24.4 M | Quarterly Volatility 7.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sensei |
Sensei Stock Ownership Analysis
About 34.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sensei Biotherapeutics recorded a loss per share of 1.19. The entity had not issued any dividends in recent years. Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Sensei Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To find out more about Sensei Biotherapeutics contact John MBA at 240 243 8000 or learn more at https://www.senseibio.com.Besides selling stocks to institutional investors, Sensei Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sensei Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sensei Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sensei Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
About 34.0% of Sensei Biotherapeutics are currently held by insiders. Unlike Sensei Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sensei Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sensei Biotherapeutics' insider trades
Sensei Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sensei Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sensei Biotherapeutics backward and forwards among themselves. Sensei Biotherapeutics' institutional investor refers to the entity that pools money to purchase Sensei Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 25.8 K | Raymond James & Associates | 2024-09-30 | 20 K | Cresset Asset Management, Llc | 2024-12-31 | 19.7 K | Hrt Financial Llc | 2024-12-31 | 11.6 K | Deuterium Capital Management, Llc | 2024-12-31 | 11 K | Morgan Stanley - Brokerage Accounts | 9.2 K | Tower Research Capital Llc | 2024-12-31 | 5.4 K | Jpmorgan Chase & Co | 2024-12-31 | 705 | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 160 | Ikarian Capital, Llc | 2024-12-31 | 650 K | Vanguard Group Inc | 2024-12-31 | 594.5 K |
Sensei Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sensei Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sensei Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sensei Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sensei Biotherapeutics Outstanding Bonds
Sensei Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sensei Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sensei bonds can be classified according to their maturity, which is the date when Sensei Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| SENMED 2927 01 NOV 51 Corp BondUS81728XAA63 | View | |
| ST 5875 01 SEP 30 Corp BondUS81725WAL72 | View | |
| US81725WAK99 Corp BondUS81725WAK99 | View | |
| SENIOR HSG PPTYS Corp BondUS81721MAM10 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| SENSATA TECHNOLOGIES INC Corp BondUS81728UAB08 | View | |
| Sensata Technologies 4375 Corp BondUS81728UAA25 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.